Empagliflozin/Linagliptin
Brand name: Glyxambi
Rank #329 of 500 drugs by total cost
Data: CMS Medicare Part D, 2023 (most current available) · Updated March 2026
$32.6M
Total Cost
34,331
Total Claims
$32.6M
Total Cost
1,387
Prescribers
$950
Cost per Claim
2,796
Beneficiaries
53,325
30-Day Fills
$24K
Avg Cost/Provider
25
Avg Claims/Provider
Share of Medicare Part D Spending
0.01%
of total Medicare Part D spending
$32.6M of $275.65B
Top Prescribers by Cost
Top 10 prescribers of $32.6M total
🔎 Data Overview
Average cost of $11,664 per patient per year. Medications at this price point significantly impact patient out-of-pocket costs and Medicare spending.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Top Prescribers of Empagliflozin/Linagliptin
| # | Provider | Specialty | Location | Claims | Cost |
|---|---|---|---|---|---|
| 1 | Nhanhau Ngo | Family Practice | Garden Grove, CA | 145 | $214K |
| 2 | Enrique Griego | Family Practice | Mcallen, TX | 131 | $206K |
| 3 | Yuan Zhang | Nurse Practitioner | New York, NY | 207 | $197K |
| 4 | Ralph Cincinnati | Nurse Practitioner | Wyomissing, PA | 190 | $190K |
| 5 | Samayra Miranda Rodriguez | Endocrinology | Dorado, PR | 228 | $188K |
| 6 | Sheila Mercado | Endocrinology | Manati, PR | 269 | $185K |
| 7 | James Barnett | Interventional Cardiology | Midland, TX | 153 | $185K |
| 8 | Duc Phan | Internal Medicine | Houston, TX | 132 | $182K |
| 9 | Daniela Dicenso | Internal Medicine | Miami, FL | 196 | $182K |
| 10 | Joanne Langton | Endocrinology | Morristown, TN | 136 | $179K |
| 11 | Lionel Velez Montijo | Internal Medicine | Bayamon, PR | 247 | $175K |
| 12 | Jose Curet Ramos | Internal Medicine | Gurabo, PR | 260 | $174K |
| 13 | Juan Ortiz Matos | Internal Medicine | Corozal, PR | 225 | $159K |
| 14 | Mark Song | Internal Medicine | Los Angeles, CA | 173 | $145K |
| 15 | Dalitza Alvarez Valentin | Endocrinology | San Juan, PR | 144 | $142K |
Top prescribers ranked by total cost for this drug in 2023.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 326 | Morphine Sulfate (Morphine Sulfate Er) | $33.2M | 1,023,056 |
| 327 | Budesonide (Budesonide Dr) | $33.1M | 120,202 |
| 328 | Mavacamten (Camzyos) | $32.8M | 3,969 |
| 329 | Empagliflozin/Linagliptin (Glyxambi) | $32.6M | 34,331 |
| 330 | Methotrexate Sodium (Methotrexate) | $32.4M | 911,965 |
| 331 | Bumetanide (Bumetanide) | $32.4M | 735,077 |
| 332 | Voxelotor (Oxbryta) | $31.5M | 2,707 |
Related Analysis
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology